BR112018069703A2 - métodos de inativação de adenovírus por calor - Google Patents
métodos de inativação de adenovírus por calorInfo
- Publication number
- BR112018069703A2 BR112018069703A2 BR112018069703A BR112018069703A BR112018069703A2 BR 112018069703 A2 BR112018069703 A2 BR 112018069703A2 BR 112018069703 A BR112018069703 A BR 112018069703A BR 112018069703 A BR112018069703 A BR 112018069703A BR 112018069703 A2 BR112018069703 A2 BR 112018069703A2
- Authority
- BR
- Brazil
- Prior art keywords
- particles
- heat
- aav
- concentration
- sample containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2523/00—Culture process characterised by temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10361—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
Abstract
a presente descrição se refere, em geral, a métodos de proteção da integridade genômica e / ou atividade biológica de partículas virais de aav em uma amostra contendo ambas partículas de aav e partículas de vírus auxiliar durante a inativação por calor. os métodos incluem o aquecimento a uma temperatura superior ou igual a 45 °c, uma amostra contendo partículas de vírus auxiliar, partículas de aav, e um tampão. o tampão inclui uma concentração de 10 mm ou superior de sais cosmotrópicos e / ou uma concentração de 10 mm ou superior de cátions bivalentes ou trivalentes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662314116P | 2016-03-28 | 2016-03-28 | |
PCT/US2017/024545 WO2017172772A1 (en) | 2016-03-28 | 2017-03-28 | Methods of heat inactivation of adenovirus |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018069703A2 true BR112018069703A2 (pt) | 2019-02-05 |
Family
ID=59966403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018069703A BR112018069703A2 (pt) | 2016-03-28 | 2017-03-28 | métodos de inativação de adenovírus por calor |
Country Status (18)
Country | Link |
---|---|
US (2) | US11013774B2 (pt) |
EP (2) | EP3436593B1 (pt) |
JP (3) | JP7356224B2 (pt) |
KR (1) | KR102389674B1 (pt) |
CN (1) | CN109196106A (pt) |
AU (1) | AU2017241777B2 (pt) |
BR (1) | BR112018069703A2 (pt) |
CA (1) | CA3018380A1 (pt) |
DK (1) | DK3436593T3 (pt) |
ES (1) | ES2938833T3 (pt) |
FI (1) | FI3436593T3 (pt) |
HU (1) | HUE061100T2 (pt) |
IL (1) | IL261914B2 (pt) |
LT (1) | LT3436593T (pt) |
PL (1) | PL3436593T3 (pt) |
PT (1) | PT3436593T (pt) |
SG (1) | SG11201808183PA (pt) |
WO (1) | WO2017172772A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2017005834A (es) | 2014-11-05 | 2017-11-17 | Voyager Therapeutics Inc | Polinucleotidos aad para el tratamiento de la enfermedad de parkinson. |
AU2015346162B2 (en) | 2014-11-14 | 2022-02-10 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
CN112375760A (zh) | 2014-11-14 | 2021-02-19 | 沃雅戈治疗公司 | 调节性多核苷酸 |
WO2016094783A1 (en) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
SG11201809699XA (en) | 2016-05-18 | 2018-12-28 | Voyager Therapeutics Inc | Modulatory polynucleotides |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
DK3898981T3 (da) | 2018-12-18 | 2024-01-22 | Ultragenyx Pharmaceutical Inc | Fremgangsmåder og sammensætninger til behandling af glykogenlagringssygdomme |
WO2023172491A1 (en) | 2022-03-07 | 2023-09-14 | Ultragenyx Pharmaceutical Inc. | Modified batch aav production systems and methods |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5387484A (en) | 1992-07-07 | 1995-02-07 | International Business Machines Corporation | Two-sided mask for patterning of materials with electromagnetic radiation |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
JP4216350B2 (ja) | 1994-09-19 | 2009-01-28 | 大日本住友製薬株式会社 | 動物細胞感染用の組換えdnaウイルスベクター |
US5872005A (en) | 1994-11-03 | 1999-02-16 | Cell Genesys Inc. | Packaging cell lines for adeno-associated viral vectors |
US6924128B2 (en) | 1994-12-06 | 2005-08-02 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
WO1996017947A1 (en) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
US5688676A (en) | 1995-06-07 | 1997-11-18 | Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
US6027931A (en) | 1995-08-03 | 2000-02-22 | Avigen, Inc. | High-efficiency AA V helper functions |
ES2099678B1 (es) * | 1995-11-03 | 1998-02-16 | Grifols Grupo Sa | Procedimiento para la inactivacion de virus en proteinas. |
US6004797A (en) | 1995-11-09 | 1999-12-21 | Avigen, Inc. | Adenovirus helper-free recombinant AAV Virion production |
JP2001506133A (ja) | 1996-12-18 | 2001-05-15 | ターゲティッド ジェネティクス コーポレイション | 組換えaavベクターの産生における使用のための、aavスプリット−パッケージング遺伝子およびこのような遺伝子を含む細胞株 |
US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6995006B2 (en) | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
CA2303768C (en) | 1997-09-19 | 2009-11-24 | The Trustees Of The University Of Pennsylvania | Methods and vector constructs useful for production of recombinant aav |
IT1297074B1 (it) | 1997-11-21 | 1999-08-03 | Angeletti P Ist Richerche Bio | Forme ormone-dipendenti delle proteine rep del virus adeno-associato (aav-2), sequenze di dna codificanti per esse, vettori che le |
JP2003528029A (ja) * | 1998-08-14 | 2003-09-24 | アヴェンティス ファーマシューティカルズ インコーポレイテッド | 遺伝子治療用のアデノウイルス配合物 |
AU764130B2 (en) | 1998-10-27 | 2003-08-14 | Crucell Holland B.V. | Improved AAV vector production |
DE19905501B4 (de) | 1999-02-10 | 2005-05-19 | MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie | Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels |
MXPA01010124A (es) * | 1999-04-09 | 2002-06-26 | Aventis Pharma Sa | Composiciones destinada a la conservacion de adenovirus recombinantes infecciosos. |
US20040235173A1 (en) | 2000-07-03 | 2004-11-25 | Gala Design, Inc. | Production of host cells containing multiple integrating vectors by serial transduction |
DE10061533B4 (de) | 2000-12-11 | 2006-05-04 | Amphenol-Tuchel Electronics Gmbh | Selbsttragende Kontaktfeder, insbesondere für einen Smartcard-Connector |
US7271002B2 (en) | 2001-11-09 | 2007-09-18 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
CA2369985A1 (en) | 2002-01-18 | 2003-07-18 | Duke University | Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach |
WO2004075861A2 (en) | 2003-02-26 | 2004-09-10 | Children's Hospital, Inc. | Recombinant adeno-associated virus production |
BRPI0511764B8 (pt) | 2004-06-01 | 2021-05-25 | Avigen Inc | método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav |
US7195394B2 (en) | 2004-07-19 | 2007-03-27 | Vijay Singh | Method for resonant wave mixing in closed containers |
US8980247B2 (en) | 2004-10-21 | 2015-03-17 | The Penn State Research Foundation | Parvovirus methods and compositions for killing neoplastic cells |
AU2006304997B2 (en) | 2005-10-20 | 2012-03-01 | Uniqure Ip B.V. | Improved AAV vectors produced in insect cells |
US9254318B2 (en) * | 2006-03-31 | 2016-02-09 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
ES2785223T3 (es) | 2006-06-21 | 2020-10-06 | Uniqure Ip Bv | Células de insecto para la producción de vectores de AAV |
GB0706638D0 (en) | 2007-04-04 | 2007-05-16 | Mbda Uk Ltd | A high-dielectric material |
US8580755B2 (en) | 2008-02-19 | 2013-11-12 | University Of Rochester | Methods and compositions for treating inflammatory conditions |
CA2742151A1 (en) | 2008-11-07 | 2010-05-14 | Intelligentnano Inc. | Transfection with magnetic nanoparticles and ultrasound |
HUE028341T2 (en) * | 2009-06-16 | 2016-12-28 | Genzyme Corp | Improved methods for purifying recombinant AAV vectors |
US20140359799A1 (en) | 2011-12-23 | 2014-12-04 | Case Western Reserve University | Targeted gene modification using hybrid recombinant adeno-associated virus |
AU2014205604B2 (en) | 2013-01-08 | 2020-01-02 | Genzyme Corporation | Use of iNOS inhibitors to increase viral yield in culture |
-
2017
- 2017-03-28 PT PT177764628T patent/PT3436593T/pt unknown
- 2017-03-28 DK DK17776462.8T patent/DK3436593T3/da active
- 2017-03-28 PL PL17776462.8T patent/PL3436593T3/pl unknown
- 2017-03-28 WO PCT/US2017/024545 patent/WO2017172772A1/en active Application Filing
- 2017-03-28 KR KR1020187030706A patent/KR102389674B1/ko active IP Right Grant
- 2017-03-28 AU AU2017241777A patent/AU2017241777B2/en active Active
- 2017-03-28 LT LTEPPCT/US2017/024545T patent/LT3436593T/lt unknown
- 2017-03-28 FI FIEP17776462.8T patent/FI3436593T3/fi active
- 2017-03-28 BR BR112018069703A patent/BR112018069703A2/pt unknown
- 2017-03-28 CA CA3018380A patent/CA3018380A1/en active Pending
- 2017-03-28 CN CN201780033212.1A patent/CN109196106A/zh active Pending
- 2017-03-28 US US16/085,177 patent/US11013774B2/en active Active
- 2017-03-28 HU HUE17776462A patent/HUE061100T2/hu unknown
- 2017-03-28 SG SG11201808183PA patent/SG11201808183PA/en unknown
- 2017-03-28 EP EP17776462.8A patent/EP3436593B1/en active Active
- 2017-03-28 EP EP22199443.7A patent/EP4159867A1/en active Pending
- 2017-03-28 JP JP2018550814A patent/JP7356224B2/ja active Active
- 2017-03-28 ES ES17776462T patent/ES2938833T3/es active Active
-
2018
- 2018-09-20 IL IL261914A patent/IL261914B2/en unknown
-
2021
- 2021-02-01 JP JP2021014329A patent/JP2021072838A/ja not_active Withdrawn
- 2021-04-23 US US17/238,743 patent/US11944658B2/en active Active
-
2022
- 2022-08-25 JP JP2022134006A patent/JP2022166304A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190083554A1 (en) | 2019-03-21 |
LT3436593T (lt) | 2023-03-10 |
EP3436593B1 (en) | 2022-11-23 |
KR20180130531A (ko) | 2018-12-07 |
EP4159867A1 (en) | 2023-04-05 |
IL261914B1 (en) | 2023-03-01 |
JP2019509747A (ja) | 2019-04-11 |
KR102389674B1 (ko) | 2022-04-21 |
US11013774B2 (en) | 2021-05-25 |
US11944658B2 (en) | 2024-04-02 |
HUE061100T2 (hu) | 2023-05-28 |
CA3018380A1 (en) | 2017-10-05 |
EP3436593A1 (en) | 2019-02-06 |
WO2017172772A1 (en) | 2017-10-05 |
JP7356224B2 (ja) | 2023-10-04 |
CN109196106A (zh) | 2019-01-11 |
DK3436593T3 (da) | 2023-02-20 |
FI3436593T3 (fi) | 2023-03-16 |
PT3436593T (pt) | 2023-01-31 |
JP2021072838A (ja) | 2021-05-13 |
IL261914A (en) | 2018-10-31 |
PL3436593T3 (pl) | 2023-03-27 |
EP3436593A4 (en) | 2019-10-16 |
AU2017241777A1 (en) | 2018-10-11 |
AU2017241777B2 (en) | 2022-02-03 |
US20220072073A1 (en) | 2022-03-10 |
SG11201808183PA (en) | 2018-10-30 |
JP2022166304A (ja) | 2022-11-01 |
IL261914B2 (en) | 2023-07-01 |
ES2938833T3 (es) | 2023-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018069703A2 (pt) | métodos de inativação de adenovírus por calor | |
BR112018074881A2 (pt) | novos vírus vaccinia geneticamente modificados | |
EA201301173A1 (ru) | Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования | |
BR112018016949A2 (pt) | vírus vaccinia atenuado competente em relação à replicação como deleção de timidina quinase com ou sem a expressão de flt3l ou gm-csf humano para imunoterapia de câncer | |
MY185320A (en) | Human antibodies to influenza hemagglutinin | |
BR112019010275A2 (pt) | adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano | |
BR112018006254A2 (pt) | camada implantável que compreende uma configuração constrita | |
MY183703A (en) | Oncolytic adenovirus encoding a b7 protein | |
BR112014018331A8 (pt) | Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação | |
BR112015007616A2 (pt) | inibidores de mek no tratamento de doenças por vírus | |
BR112014004860A2 (pt) | composições de anticorpo contra vírus da influenza | |
BR112015012536A2 (pt) | tratamento de câncer com inibidores heterocíclicos da glutaminase | |
BR112015031509A2 (pt) | Polipeptídeo, molécula de ácido nucleico, vetor, e, composição | |
BR112014005404A8 (pt) | Citomegalovírus (cmv) defectivo em replicação condicional, composição, uso da composição, método para preparo de cmv defectivo em replicação condicional, e, uso do cmv defectivo em replicação condicional | |
BRPI1012749A8 (pt) | molécula de ligação, variante funcional da molécula de ligação, imunoconjugado, composição farmacêutica, uso da molécula de ligação, molécula de ácido nucléico. vetor, hospedeiro, e , método para produzir uma molécula de ligação. | |
BR112015020235A2 (pt) | fragmento biologicamente ativo de proteína csf-1 ou um seu homólogo, ácido nucléico, proteína de fusão, ácido nucléico isolado, vetor, célula hospedeira, método de realização da proteína de fusão do primeiro aspeto da invenção, composição, utilização de uma proteína de fusão, método de tratamento para um indivíduo sofrendo de cancro do fígado e que irá ser submetido a cirurgia, método de tratamento para um indivíduo que irá ser submetido a cirurgia de transplante de fígado, e, kit | |
BR112019009256A2 (pt) | métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo | |
CO6440541A2 (es) | Virus de diarrea viral bovina con una proteina erns modificada | |
CL2023000629A1 (es) | Partículas virales modificadas y usos de estas | |
CO7461133A2 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
BR112019007147A2 (pt) | anticorpos anti-o1 e usos dos mesmos | |
BR112015022907A2 (pt) | formas de sal de (2-(2-(4-fluorfenil)tiazol-4-il) propan-2-il) carbamato de (s)-quinuclidin-3-ila | |
BR112017018963A2 (pt) | método para tratar anemia por deficiência de ferro | |
MX2019004029A (es) | Compuestos y metodos para diagnosis y tratamiento de infecciones virales. | |
BR112021022951A2 (pt) | Composições e métodos para o tratamento de doenças mediadas por atpase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: ULTRAGENYX PHARMACEUTICAL INC. (US) |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |